Study of effect of subcutaneous enoxaparin sodium injection duration on incidence and extent of bruising at injection site in hospitalized patients.

Study of effect of subcutaneous enoxaparin sodium injection duration on incidence and extent of bruising at injection site in hospitalized patient.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015032721547N1

Enrollment

112

Registered

2015-06-14

Start date

2015-05-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

?Bruising in site of enixaparin sodium injection. Hemorrhage in any site resulting from a procedure

Interventions

Intervention 1: Group A: Samples(n=56) will receive pre-filled syring of enoxaparin sodium 6000 IU (prepared by Alborzdarou company), subcutaneously in two sequence days and in two methods of 1 (drug

Prevention

Group A: Samples(n=56) will receive pre-filled syring of enoxaparin sodium 6000 IU (prepared by Alborzdarou company), subcutaneously in two sequence days and in two methods of 1 (drug injection in 10

Group B: Samples(n=56) will receive pre-filled syring of enoxaparin sodium 6000 IU (prepared by Alborzdarou company), subcutaneously in two sequence days and in two methods of 2 (injection for 20 sec

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients being in the first 24 hours of hospitalization in cardiac care unit who need to remain hospitalized for at least another 48 hours; coagulation tests results within therapeutic range; written order for subcutaneous 6000 IU enoxaparin sodium in patients`record; no special treatments required (fibrinolytic therapy, angioplasty,...), widespread skin lesions on the right side of the abdomen or any blood and liver diseases and signing written consent form to participate in the study. Exclusion criteria: Any changes in drug order or dosage, discharge before data selection time duration and death of a patient .

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The incidence of bruising in site of enoxaparin sodium injection. Timepoint: 48 hours after intervention. Method of measurement: Recording the observed bruising in prepared form.;The extent of bruising in area of Enoxaparin sodium in Milimeter. Timepoint: 48 hours after intervention. Method of measurement: Recording the bruising extent (by flexible ruler in milimeter) in prepared form.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShirin Jafroudi

Beheshti nursing and midwifery college, Guilan university of medical sciences

s_jafroudi@gums.ac.ir+98 13 3355 5056

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026